Education
About Us
Working with TipRanks
Follow Us
Sanara MedTech (SMTI)
:SMTI
SMTI Stock Chart & Stats
$29.52
$0.13(0.40%)
At close: 4:00 PM EST
$29.52
$0.13(0.40%)
Day’s Range― - ―
52-Week Range$19.06 - $38.75
Previous CloseN/A
Volume5.72K
Average Volume (3M)47.21K
Market Cap
$170.31M
Enterprise Value$306.80M
Total Cash (Recent Filing)$14.94M
Total Debt (Recent Filing)$47.39M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Apr 01, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.40
Shares Outstanding8,935,657
10 Day Avg. Volume91,934
30 Day Avg. Volume47,210
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)7.15
Price to Sales (P/S)3.25
P/FCF Ratio-1.23K
Enterprise Value/Market Cap1.80
Enterprise Value/Revenue3.01
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-11.45
Forecast
1Y Price Target
$41.00Price Target Upside38.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2
Revenue Forecast (FY)$105.75M
Bulls Say, Bears Say
Bulls Say
Product Sales GrowthSales of surgical soft tissue repair products grew 24% YoY to $23.4M, driven by increased demand for CellerateRX Surgical and BIASURGE.
ProfitabilityContinuing operations become profitable in 3Q25.
Revenue GrowthSanara MedTech reported a net revenue of $25.8M in 2Q25, showing 28% year-over-year growth and surpassing projections.
Bears Say
Debt ObligationsThe company has $44.2M of principal debt obligations, indicating a significant financial commitment.
Net LossNet loss was $30.4M, or ($3.52) per share, more than our estimated loss of $2.2M due to an asset impairment charge of $26.5M.
Strategic RealignmentThe company announced that it had completed its previously announced evaluation of strategic alternatives for Tissue Health Plus (THP) and initiated a strategic realignment of its business, which involves discontinuing THP to improve operating efficiency.
Sanara MedTech News
SMTI FAQ
What was Sanara MedTech’s price range in the past 12 months?
Sanara MedTech lowest stock price was $19.06 and its highest was $38.75 in the past 12 months.
What is Sanara MedTech’s market cap?
Sanara MedTech’s market cap is $170.31M.
When is Sanara MedTech’s upcoming earnings report date?
Sanara MedTech’s upcoming earnings report date is Apr 01, 2026 which is in 131 days.
How were Sanara MedTech’s earnings last quarter?
Sanara MedTech released its earnings results on Nov 12, 2025. The company reported -$3.4 earnings per share for the quarter, missing the consensus estimate of -$0.215 by -$3.185.
Is Sanara MedTech overvalued?
According to Wall Street analysts Sanara MedTech’s price is currently Undervalued.
Does Sanara MedTech pay dividends?
Sanara MedTech does not currently pay dividends.
What is Sanara MedTech’s EPS estimate?
Sanara MedTech’s EPS estimate is 0.33.
How many shares outstanding does Sanara MedTech have?
Sanara MedTech has 8,935,657 shares outstanding.
What happened to Sanara MedTech’s price movement after its last earnings report?
Sanara MedTech reported an EPS of -$3.4 in its last earnings report, missing expectations of -$0.215. Following the earnings report the stock price went down -24.715%.
Which hedge fund is a major shareholder of Sanara MedTech?
Currently, no hedge funds are holding shares in SMTI
Sanara MedTech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.00 (38.89% Upside)
$41.00 (38.89% Upside)
Blogger Sentiment
Bullish
SMTI Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.41%
12-Months-Change
Fundamentals
Return on Equity
-27.19%
Trailing 12-Months
Asset Growth
-19.71%
Trailing 12-Months
Company Description
Sanara MedTech
Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care and regenerative medicine products. The company operates primarily in the healthcare sector, offering innovative solutions designed to improve patient outcomes and promote healing in chronic and acute wounds. Sanara's core product portfolio includes advanced wound dressings and bioactive solutions that utilize its proprietary technologies to facilitate tissue regeneration and healing processes.
SMTI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Sanara MedTech demonstrated strong revenue growth and improved profitability, driven by its core surgical business and strategic network expansion. However, the discontinuation of Tissue Health Plus and increased operating expenses pose challenges.View all SMTI earnings summariesSMTI Stock 12 Month Forecast
Average Price Target
$41.00
▲(38.89% Upside)
Technical Analysis
InfuSystem Holdings
―
Orasure Technologies
―
Stereotaxis
―
Utah Medical Products
―
Sharps Technology, Inc.
―
Ownership Overview
41.76% Insiders
3.15% Mutual Funds
1.53% Other Institutional Investors
50.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---